Dementia

Dementia represents one of the greatest challenges associated with population ageing. The term “dementia” describes a variety of brain disorders, including Alzheimer’s disease, which progressively lead to brain damage and cause a gradual deterioration of a person’s functional capacity and social relations. Despite billions of dollars spent on research into dementia-related disorders, there is no cure, and substantially disease-modifying treatments may only now be emerging.

More than 21 million people in OECD countries are estimated to have dementia in 2021. If current trends continue, this number will double by 2050, reaching nearly 42 million people across OECD countries. Age remains the greatest risk factor for dementia: across the 38 OECD countries, average dementia prevalence rises from 2.2% among people aged 65-69 to nearly 42% among people aged 90 or older. This means that as countries age, the number of people living with dementia will also increase – particularly as the proportion of the population over 80 rises. Already, countries with some of the oldest populations among OECD countries – including Japan, Italy and Germany – also have the highest prevalence of dementia. Across OECD countries on average, 16 people per 1 000 population are estimated to have dementia (Figure 10.8). In eight countries, more than 20 people per 1 000 population are living with a dementia disorder. By 2050, all but five OECD member countries (the Czech Republic, Hungary, Israel, Mexico and the Slovak Republic) will have a dementia prevalence of more than 20 people per 1 000 population, while in five countries (Greece, Italy, Japan, Korea and Spain), more than one in 25 people will be living with dementia.

Even though treatment is not available in most OECD countries, there is much that health and social care systems can do to improve care and the quality of life for people living with dementia and their families. In recent years, at least 25 OECD countries have developed or announced national plans or strategies for dementia, and increasing attention is being paid to reducing stigma around dementia, and to adapting communities and care facilities to meet the needs of people with dementia (OECD, 2018[1]).

Although antipsychotic drugs can reduce the behavioural and psychological symptoms that affect many people with dementia, the availability of effective non-pharmacological interventions – as well as the associated health risks and ethical issues of antipsychotic medication – means that they are only recommended as a last resort. However, inappropriate use of these drugs remains widespread, and reducing their overuse is a policy priority for many OECD countries. Across 19 OECD countries in 2019, more than 5% of adults aged 65 and over received a prescription for antipsychotic medicines. This masks the wide variation in prescribing rates between countries. Excluding Latvia, antipsychotic prescribing varies by a factor of six across most OECD countries, from just 16 prescriptions per 1 000 people aged 65 and over in Sweden to 97 prescriptions per 1 000 in Ireland. Moreover, age-standardised rates of antipsychotic prescribing were higher for women than for men in every OECD country. On average across 19 OECD countries, women were 31% more likely to be prescribed antipsychotic medication than men (Figure 10.9).

People living with dementia have been severely affected by the COVID-19 pandemic. Measures put in place to contain the virus – notably strict bans or limitations on visitors to LTC facilities – dramatically increased social isolation. The longer-term impacts of the containment measures put in place to control the pandemic may have negative impacts on cognitive decline and well-being among many living with dementia.

Metadata, Legal and Rights

This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. Extracts from publications may be subject to additional disclaimers, which are set out in the complete version of the publication, available at the link provided.

© OECD 2021

The use of this work, whether digital or print, is governed by the Terms and Conditions to be found at http://www.oecd.org/termsandconditions.